English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessZydus gets EIR from USFDA for Pharma SEZ plant at Ahmedabad

    Zydus gets EIR from USFDA for Pharma SEZ plant at Ahmedabad

    The plant had completed the United States Food and Drug Administration (USFDA) audit from January 16-24, 2017, Zydus Cadila said in a statement. The company's "formulations manufacturing facility at Pharma SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA signifying the successful closure of the audit", it added.

    August 29, 2017 / 13:17 IST
    Aurobindo Pharma Ltd.

    Aurobindo Pharma Ltd.

     
     
    live
    • bselive
    • nselive
    Volume
    Todays L/H
    More

    Drug firm Zydus Cadila today said it has received establishment inspection report from the US health regulator for its manufacturing facility at Pharma SEZ at Ahmedabad.

    The plant had completed the United States Food and Drug Administration (USFDA) audit from January 16-24, 2017, Zydus Cadila said in a statement. The company's "formulations manufacturing facility at Pharma SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA signifying the successful closure of the audit", it added.

    Shares of Cadila Healthcare, the listed entity of Zydus Group were today trading at Rs 499.75 per scrip in the afternoon trade on BSE, down 0.26 per cent from the previous close.

    first published: Aug 29, 2017 01:03 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347